Bioharvest Sciences Inc 6-K, filed Oct 29, 2024
Bioharvest Sciences Inc. (BHST)
About this 6-K
Bioharvest Sciences Inc filed this 6-K on October 29, 2024.
|
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
FORM 6-K
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the month of October 2024
Commission file number: 000-56663
BIOHARVEST SCIENCES INC.
(Exact name of Registrant as specified in its charter)
Not applicable
(Translation of Registrant’s name into English)
1140-625 Howe Street, Vancouver, British Columbia V6C 2T6, Canada
(Address of principal executive offices)
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
☒ Form 20-F ☐ Form 40-F
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ☐
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ☐
|
Exhibits:
Exhibit | Description |
Material Change Report dated October 28, 2024 |
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
| BIOHARVEST SCIENCES INC. |
| (Registrant) |
|
|
Date: October 28, 2024 | /s/ David Ryan |
| Name: David Ryan |
| Title: Vice-President, Investor Relations, & Secretary |
FORM 51-102F3
MATERIAL CHANGE REPORT
Item 1.Name and Address of Company
BIOHARVEST SCIENCES INC.
Suite 1140 – 625 Howe Street
Vancouver, BC, V6C 2T6
(the “Company”)
Item 2.Date of Material Change
October 28, 2024
Item 3.News Release
The news release (the “News Release”) was issued and disseminated on October 28, 2024.
Item 4.Summary of Material Change
Bar Dichter was appointed as the new Chief Financial Officer of the Company following the resignation of Alan Rootenberg.
Item 5.Full Description of Material Change
See the News Release attached hereto as Schedule “A”.
Item 6.Reliance on Subsection 7.1(2) of National Instrument 51-102
Not applicable.
Item 7.Omitted Information
None.
Item 8.Executive Officer
For further information, please contact:
David Ryan
Secretary and VP, Investor Relations
604 622-1187
Item 9.Date of Report
October 28, 2024
SCHEDULE “A”
NEWS RELEASE
(See attached)
BioHarvest Sciences Appoints Bar Dichter as CFO |
Vancouver, British Columbia and Rehovot, Israel – October 28, 2024 – BioHarvest Sciences Inc. (“BioHarvest” or the “Company”) (CSE: BHSC) (OTCQB: CNVCF), (“BioHarvest” or the “Company”) (CSE: BHSC) (OTCQB: CNVCF), a company pioneering its patented Botanical Synthesis technology process, today announced the appointment of Bar Dichter (née Moreh) as Chief Financial Officer of the Company.
Ms. Dichter joined the Company as Controller in 2018, and was promoted to Vice President, Finance for the Company in July 2022. Prior to joining the Company, Ms. Dichter worked in the audit department of KPMG Israel. This appointment of Ms. Dichter as full-time CFO ensures compliance with Nasdaq listing requirements.
Ms. Dichter holds a Bachelor of Arts, Accounting and Economics (2016) from Tel-Aviv University in Israel and an MBA, Finance and Financial Management Services (2018) from the College of Management Academic Studies in Israel. She was registered as a CPA in Israel in 2018.
Ilan Sobel, Chief Executive Officer, said: “Ms. Dichter has demonstrated a deep understanding of our Company’s business as well as the leadership qualities needed to support the Company’s growth and implement our capital markets strategy. This promotion of Ms. Dichter continues BioHarvest’s proud history of promoting from within, as well as senior female leadership across the Company. On behalf of the Board, I would like to thank Mr. Rootenberg – our previous fractional Chief Financial Officer – for his commitment, partnership and significant contribution to the business the past 4 years.
About BioHarvest Sciences Inc.
BioHarvest Sciences Inc. (CSE: BHSC) (OTCQB: CNVCF) (FSE: 8MV0) is a leader in Botanical Synthesis, leveraging its patented technology platform to grow plant-based molecules, without the need to grow the underlying plant. BioHarvest is leveraging its botanical synthesis technology to develop the next generation of science-based and clinically proven therapeutic solutions within two major business verticals; as a contract development and production organization (CDMO) on behalf of customers seeking complex molecules, and as a creator of proprietary nutraceutical health and wellness products, which includes dietary supplements. To learn more, please visit www.bioharvest.com.
Forward-Looking Statements
Information set forth in this news release might include forward-looking statements that are based on management's current estimates, beliefs, intentions, and expectations, and are subject to a number of risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. All forward-looking statements are inherently uncertain and actual results may be affected by a number of material factors beyond our control. Readers should not place undue reliance on forward-looking statements. BHSC does not intend to update forward-looking statement disclosures other than through our regular management discussion and analysis disclosures.
The Canadian Securities Exchange has neither approved nor disapproved the information contained herein and does not accept responsibility for the adequacy or accuracy of this news release.
This release has been reviewed and approved by Dave Ryan, VP Investor Relations, who accepts responsibilities for its contents.
BioHarvest Corporate Contact:
Dave Ryan, VP Investor Relations & Director
+1 (604) 622-1186
info@bioharvest.com
Investor Relations Contact:
Lucas A. Zimmerman
Managing Director
MZ Group - MZ North America
+1 (949) 259-4987
BHSC@mzgroup.us